潜在的代谢性疾病治疗靶点——固醇调节元件结合蛋白  

SREBPs: a Potential Therapeutic Target for Metabolic Diseases

作　　者：耿得珍 卜亚茹 焦波[1] GENG De-zhen;BU Ya-ru;JIAO Bo(Institute of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China)

机构地区：[1]山东大学药学院新药药理研究所

出　　处：《中国药学杂志》2019年第15期1205-1210,共6页Chinese Pharmaceutical Journal

摘　　要：固醇调节元件结合蛋白(sterol regulatory element binding proteins,SREBPs)是调节胆固醇,脂肪酸和甘油三酯生物合成的主要转录因子,控制着脂肪生成和摄取等关键基因的表达。笔者总结了SREBPs的激活机制及其与胰岛素、环磷腺苷、肝脏X受体等相互作用,共同参与脂质代谢的过程,并结合最新研究动态对SREBPs的功能进行阐述。这些发现表明,抑制SREBPs可以成为治疗代谢性疾病的新策略,如Ⅱ型糖尿病,胰岛素抵抗,脂肪肝、动脉粥样硬化以及相关肿瘤等。Sterol regulatory element binding proteins (SREBPs) are the major transcription factors regulating cholesterol, fatty acid and triglyceride biosynthesis and control the expression of key genes such as lipogenesis and uptake. In this review, we summarize the processing of SREBPs and their interactions with insulin, cyclic adenosine monophosphate (cAMP), and liver X receptor (LXR) for the synthesis and metabolism of lipid, and combine the latest researches to illustrate the function of SREBPs. These findings suggest that inhibition of SREBPs can be a new strategy for the treatment of metabolic diseases, such as type Ⅱ diabetes, insulin resistance, fatty liver, atherosclerosis and tumors.

关 键 词：固醇调节元件结合蛋白 脂质代谢 胰岛素 CAMP 肝脏X受体 代谢性疾病 

分 类 号：R965[医药卫生—药理学]